Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%. The stock has ...

“Gilead has a legacy of bringing groundbreaking ... ASSURE is an open label study to evaluate the long-term safety and tolerability of seladelpar in people with primary biliary cholangitis ...

Seladelpar Would Provide an Important Treatment Option for People Living with the Rare Liver Disease in the EU – FOSTER CITY, Calif., December 13, 2024--(BUSINESS WIRE)--Gilead Sciences ...

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

Gilead (GILD) Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending seladelpar for the treatment of ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...

Gilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) recommended approval of seladelpar.

December 17, 2024--Gilead Sciences, Inc. (Nasdaq ... adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic ...

Recall that seladelpar's FDA approval for primary biliary cholangitis [PBC] was expected in August and would open a ~$3 billion PBC market up to Gilead. Let's see how things have played out since ...